[Ischemic stroke in young patients and/or livedo: is it important to look for anti-beta 2-glycoprotein I antibodies?].
This study was aimed at determining the prevalence of anti-beta 2glycoprotéine I antibodies (anti-beta 2-GPI antibodies) in young adult patients presenting with either livedo reticularis or ischemic stroke. Forty patients referred between February 1996 and February 1997 underwent clinical examination and laboratory tests with search for anticardiolipin antibodies (ACL antibodies), lupus anticoagulant (LA) and anti-beta 2GPI antibodies. Twenty-one patients presented with ischemic stroke (one with ACL antibodies), 13 had livedo (six with ACL antibodies, two with LA) and six patients presented with Sneddon's syndrome (two with ACL antibodies, two with LA). Only one was positive for anti-beta 2-GPI antibodies. beta 2-GPI is a cofactor that increases anticardiolipin antibody adhesion to cardiolipin. Our results suggest that the prevalence of anti-beta 2GPI antibodies is not high in young patients with either livedo reticularis or ischemic stroke. However, due to the small number of patients included in the study, definite conclusions may not be drawn out. Anti-beta 2-GPI antibodies assay is not justified in routine evaluation of patients with either livedo reticularis or ischemic stroke.